Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y(12) Inhibitors is Not Feasible or Desirable, in Spain

PURPOSE: Cangrelor is an intravenous, direct-acting, reversible P2Y(12) inhibitor indicated for the reduction of thrombotic cardiovascular events in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) in whom oral P2Y(12) inhibitors are not feasible or des...

Descripción completa

Detalles Bibliográficos
Autores principales: Lizano-Díez, Irene, Paz Ruiz, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850430/
https://www.ncbi.nlm.nih.gov/pubmed/33536769
http://dx.doi.org/10.2147/CEOR.S290377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850430/
https://www.ncbi.nlm.nih.gov/pubmed/33536769
http://dx.doi.org/10.2147/CEOR.S290377

Ejemplares similares